Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
Rhea-AI Summary
Valion Bio (NASDAQ: VBIO), a late-stage biopharma company, highlighted a U.S. House Armed Services Committee FY27 NDAA report directive for a resources and fielding plan prioritizing radiation/nuclear countermeasures that are both prophylactic and therapeutic.
This aligns with Valion Bio's lead candidate, Entolimod, which has shown survival benefit as a radioprotectant and radiomitigant in non-human primate studies under the FDA Animal Rule.
Positive
- U.S. House Armed Services Committee FY27 NDAA report prioritizes dual-use radiation countermeasures
- Directive seeks resources and fielding plan for prophylactic and therapeutic radiation/nuclear countermeasures
- Entolimod positioned as both radioprotectant and radiomitigant for acute radiation syndrome
- Non-human primate studies show Entolimod survival benefit under FDA Animal Rule
- Recent briefings to ASD (ND-CBD) and BARDA increase U.S. defense visibility for Entolimod
Negative
- Entolimod efficacy data disclosed only from non-human primate studies, not human trials
News Market Reaction – VBIO
In the Jun 11 session, VBIO declined 24.75%, reflecting a significant negative market reaction. Argus tracked a peak move of +20.0% during that session. Argus tracked a trough of -44.9% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 35.5x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 19 | Government briefing | Positive | +2.9% | Briefed senior DoW and BARDA officials on Entolimod for acute radiation syndrome. |
| May 14 | Platform licensing deal | Positive | -5.5% | Velocity Bioworks secured exclusive commercial license for LarmorBio’s BioScan-NMR™ platform. |
| May 14 | Q1 2026 earnings | Negative | -5.5% | Reported Q1 2026 results with $5.6M operating expenses, $6.2M net loss, $7.2M cash. |
| May 11 | Earnings announcement date | Neutral | +15.6% | Announced timing of Q1 2026 results and related conference call and webcast details. |
| May 06 | Facility opening | Positive | +2.0% | Opened Velocity Bioworks biomanufacturing facility to support Entolimod and CDMO activities. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News tied to Entolimod, facilities, and government engagement has often seen modestly positive or mixed reactions, while licensing and earnings news have produced both declines and sharp rallies, indicating inconsistent trading responses to fundamentally positive updates.
Over the past months, Valion Bio has advanced multiple initiatives around Entolimod and its Velocity Bioworks platform. In May 2026, the company opened a biomanufacturing facility in San Antonio and later reported Q1 2026 results, with the stock reacting negatively. A subsequent exclusive license for the BioScan-NMR™ platform also saw a decline. However, government- and preparedness-focused updates, including briefings to DoW and BARDA on Entolimod, have aligned with positive or modestly positive price moves. Today’s Committee-focused news continues that defense-readiness narrative.
Key Terms
acute radiation syndrome medical
radioprotectant medical
radiomitigant medical
recombinant medical
tlr5 medical
apoptosis medical
non-human primate medical
animal rule regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Emanates from the FY27 NDAA process underway in the
Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant)
Follows Company's two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome
The Committee's focus on radiation/nuclear countermeasures addresses an important force protection and readiness challenge by emphasizing medical countermeasures that offer both prophylactic as well as therapeutic efficacy. This requirement supports a comprehensive strategy for developing sustainable approaches to emerging threats, and, specifically, it positions the Department of War ("DoW") in an advanced state of readiness and response to radiation and nuclear exposures.
The development closely follows [comes on the heels of] Valion Bio's April 2026 briefing to the ASD (ND-CBD) and its May 2026 briefing to the Biomedical Advanced Research and Development Authority (BARDA) about its lead candidate, Entolimod.
Entolimod is a recombinant deletion variant of Salmonella FliC flagellin engineered to activate TLR5 selectively. Upon engagement, Entolimod triggers specific pathways that ultimately promote multi-tissue cytoprotection and inhibit apoptosis in radiosensitive hematopoietic and gastrointestinal tissues. The compound has demonstrated survival benefit as both a radioprotectant and a radiomitigant in controlled non-human primate studies under the
Valion Bio CEO, Michael Handley, said , "For too long, nuclear/radiation preparedness has relied on agents that can only be used after the damage is done. We strongly commend the Committee for recognizing that the nation needs a radiation countermeasure, such as Entolimod, that works both before and after exposure. And we're incredibly energized that the highest levels of the
About Valion Bio, Inc.
Valion Bio, Inc. (Nasdaq: VBIO), the new corporate identity of Tivic Health Systems, Inc., is developing biologics that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease, and immune dysregulation. The Company's lead candidate, Entolimod for acute radiation syndrome (ARS), has been extensively studied and has demonstrated survival benefits and improved tissue recovery in animal models under the FDA's Animal Rule. Entolimod is a novel Toll-like receptor 5 (TLR5) agonist that activates NF-κB signaling pathways to protect cells from damage and stimulate immune responses. Entolimod for ARS has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration. Valion Bio is also advancing Entolasta, a next-generation TLR5 agonist designed for potential broader therapeutic applications, including oncology supportive care. Valion Bio's wholly owned subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that offers biomanufacturing services to third-party biotech companies. Valion Bio also leverages Velocity Bioworks' manufacturing capabilities to advance its own drug pipeline with the expected benefits of lower costs, accelerated manufacturing outcomes, and supply chain security.
For more information, visit www.valionbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Entolimod's potential alignment with defense requirements, the potential for government prioritization, funding, or procurement, and the Company's development plans. The FY27 NDAA report language does not reference Valion Bio or Entolimod, and does not constitute a DoW contract, grant, procurement, award, or funding commitment to the Company. There can be no assurance that Valion Bio will receive any government funding, contract, or procurement, or that Entolimod will be selected for any government program. Words such as "encouraged," "positions," "potential," and similar expressions identify forward-looking statements. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including, without limitation, the uncertain outcome of the FY27 NDAA process, the absence of any assurance of government funding, contract, or procurement, the risks and timing of regulatory review and potential approval under the FDA's Animal Rule, and the other risk factors described in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statement except as required by law.
Investor + Media Contact:
Rich Cockrell
CG Capital
vbio@cg.capital
View original content to download multimedia:https://www.prnewswire.com/news-releases/valion-bio-nasdaq-vbio-confirms-us-house-armed-services-committee-initiative-to-address-urgent-need-for-radiation-nuclear-countermeasures-302797721.html
SOURCE Valion Bio, Inc.